Boolean operators and controlled vocabulary (e.g., MeSH terms) were used to combine keywords related to GLP-1 RAs (e.g., “liraglutide,” “semaglutide,” “exenatide”), type 2 diabetes (“T2DM,” “type 2 diabetes mellitus”), and relevant clinical outcomes (e.g., “major adverse cardiovascular events,” “MACE,” “renal outcomes,” “nephropathy”). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.